Home LiteratureArticle Details
PMID: 21317394 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 186 ·No. 6 ·2011-03-15 ·Pages 3327-35

Salagianni M, Lekka E, Moustaki A, Iliopoulou EG, Baxevanis CN, Papamichail M, Perez SA

Abstract

Previous work from our laboratory showed that hydrocortisone (HC) combined with IL-15 induces expansion of activated human NK cells. We set up an experimental tumor model to evaluate the use of adoptively transferred, HC plus IL-15 (HC/IL-15)-activated and -expanded murine NK cells in the treatment of syngeneic mice carrying established lung metastases of the CT26 transplantable tumor. We also examined the effect of denileukin diftitox (Ontak) on the depletion of regulatory T cells to enhance the in vivo antitumor immunity induced by the adoptively transferred NK cells. Our results clearly demonstrate that murine DX5(+) NK cells are largely expanded in the presence of IL-15 plus HC while retaining intact their functional status. Moreover, when intravenously infused, they mediated significant antitumor responses against CT26 lung tumors in syngeneic BALB/c animals that were further enhanced upon pretreatment of the tumor-bearing animals with Ontak. Total splenocytes and isolated splenic T cells from NK-treated mice responded in vitro against CT26 tumor cells as evidenced by IFN-γ-based ELISPOT, proliferation, and cytotoxicity assays. Importantly, animals treated with Ontak plus adoptive transfer of HC/IL-15-expanded NK cells significantly retarded CT26 tumor growth after a rechallenge with the same tumor s.c. in their flanks. Taken altogether, our data suggest that NK cell adoptive transfer can trigger adaptive antitumor T cell responses, and regulatory T cell depletion by Ontak is mandatory for enabling HC/IL-15-activated NK cells to promote long-lasting adaptive antitumor immunity.

MeSH Terms
Adaptive Immunity Adoptive Transfer/methods Animals Antineoplastic Agents/administration & dosage,therapeutic use Cell Proliferation/drug effects Cells, Cultured Colonic Neoplasms/drug therapy,immunology,secondary Diphtheria Toxin/administration & dosage,therapeutic use Hydrocortisone/administration & dosage,therapeutic use Interleukin-15/administration & dosage Interleukin-2/administration & dosage,therapeutic use Killer Cells, Natural/cytology,immunology,transplantation Lung Neoplasms/drug therapy,immunology,pathology Lymphocyte Activation/drug effects,immunology Lymphocyte Depletion/methods Mice Mice, Inbred BALB C Random Allocation Recombinant Fusion Proteins/administration & dosage,therapeutic use T-Lymphocytes, Regulatory/drug effects,immunology,pathology
Chemicals
Antineoplastic Agents Diphtheria Toxin Interleukin-15 Interleukin-2 Recombinant Fusion Proteins denileukin diftitox Hydrocortisone
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Salagianni Maria
Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens 115 22, Greece.
Lekka Eftychia
Moustaki Ardiana
Iliopoulou Eleni G
Baxevanis Constantin N
Papamichail Michael
Perez Sonia A
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
1550-6606
Published
2011-03-15
Epub
2011-00-11
Pages
3327-35
Language
English
Region
United States
NLM ID
2985117R
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com